{"id":661,"date":"2014-07-23T03:57:51","date_gmt":"2014-07-23T03:57:51","guid":{"rendered":"https:\/\/blogs.bmj.com\/jmg\/?p=661"},"modified":"2026-02-25T19:44:43","modified_gmt":"2026-02-25T19:44:43","slug":"long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jmg\/2014\/07\/23\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\/","title":{"rendered":"Long-term prospective clinical follow-up after BRCA1\/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies (Contributed by Prof. D Gareth Evans)"},"content":{"rendered":"<p>The risks of breast cancer associated with gene faults in <em>BRCA1<\/em> and<em> BRCA2<\/em> have been reported to vary from as little as 30% (especially BRCA2) to as high as 90% by age 70 years. However, most studies that assessed risk look backwards at what has happened in families rather than forwards. These studies make adjustments for biases, but include women born before 1930 when breast cancer incidence rates were much lower. We assessed breast cancer risk prospectively in 254 unaffected women with <em>BRCA1<\/em> and 238 with <em>BRCA2<\/em> mutations.Nineteen breast cancers occurred in <em>BRCA1 <\/em>and 23 in <em>BRCA2<\/em>. Estimates of risk to 70 years of were 55.1% for <em>BRCA1<\/em> and 71.5% for<em> BRCA2<\/em>. Breast cancers were associated with stronger family histories especially for <em>BRCA2<\/em>. (<a href=\"http:\/\/jmg.bmj.com\/content\/early\/2014\/07\/22\/jmedgenet-2014-102336\">http:\/\/jmg.bmj.com\/content\/early\/2014\/07\/22\/jmedgenet-2014-102336<\/a> )<\/p>\n<p><a href=\"https:\/\/blogs.bmj.com\/jmg\/files\/2014\/07\/evanstonightPic.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-662\" src=\"https:\/\/blogs.bmj.com\/jmg\/files\/2014\/07\/evanstonightPic-300x225.jpg\" alt=\"evanstonightPic\" width=\"300\" height=\"225\" srcset=\"https:\/\/blogs.bmj.com\/jmg\/files\/2014\/07\/evanstonightPic-300x225.jpg 300w, https:\/\/blogs.bmj.com\/jmg\/files\/2014\/07\/evanstonightPic.jpg 640w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The risks of breast cancer associated with gene faults in BRCA1 and BRCA2 have been reported to vary from as little as 30% (especially BRCA2) to as high as 90% by age 70 years. However, most studies that assessed risk look backwards at what has happened in families rather than forwards. These studies make adjustments [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/jmg\/2014\/07\/23\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":123,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-661","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Long-term prospective clinical follow-up after BRCA1\/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies (Contributed by Prof. D Gareth Evans) - JMG Contact blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jmg\/2014\/07\/23\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Long-term prospective clinical follow-up after BRCA1\/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies (Contributed by Prof. D Gareth Evans) - JMG Contact blog\" \/>\n<meta property=\"og:description\" content=\"The risks of breast cancer associated with gene faults in BRCA1 and BRCA2 have been reported to vary from as little as 30% (especially BRCA2) to as high as 90% by age 70 years. However, most studies that assessed risk look backwards at what has happened in families rather than forwards. These studies make adjustments [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jmg\/2014\/07\/23\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\/\" \/>\n<meta property=\"og:site_name\" content=\"JMG Contact blog\" \/>\n<meta property=\"article:published_time\" content=\"2014-07-23T03:57:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-25T19:44:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogs.bmj.com\/jmg\/files\/2014\/07\/evanstonightPic.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"480\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"hqqu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@HuiQiQu\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hqqu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2014\\\/07\\\/23\\\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2014\\\/07\\\/23\\\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\\\/\"},\"author\":{\"name\":\"hqqu\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\"},\"headline\":\"Long-term prospective clinical follow-up after BRCA1\\\/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies (Contributed by Prof. D Gareth Evans)\",\"datePublished\":\"2014-07-23T03:57:51+00:00\",\"dateModified\":\"2026-02-25T19:44:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2014\\\/07\\\/23\\\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\\\/\"},\"wordCount\":144,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2014\\\/07\\\/23\\\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2014\\\/07\\\/evanstonightPic-300x225.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2014\\\/07\\\/23\\\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2014\\\/07\\\/23\\\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2014\\\/07\\\/23\\\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\\\/\",\"name\":\"Long-term prospective clinical follow-up after BRCA1\\\/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies (Contributed by Prof. D Gareth Evans) - JMG Contact blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2014\\\/07\\\/23\\\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2014\\\/07\\\/23\\\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2014\\\/07\\\/evanstonightPic-300x225.jpg\",\"datePublished\":\"2014-07-23T03:57:51+00:00\",\"dateModified\":\"2026-02-25T19:44:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2014\\\/07\\\/23\\\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2014\\\/07\\\/23\\\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2014\\\/07\\\/23\\\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2014\\\/07\\\/evanstonightPic.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2014\\\/07\\\/evanstonightPic.jpg\",\"width\":640,\"height\":480},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2014\\\/07\\\/23\\\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Long-term prospective clinical follow-up after BRCA1\\\/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies (Contributed by Prof. D Gareth Evans)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"name\":\"JMG Contact blog\",\"description\":\"JMG Contact blog\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\",\"name\":\"JMG Contact blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"width\":300,\"height\":34,\"caption\":\"JMG Contact blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\",\"name\":\"hqqu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"caption\":\"hqqu\"},\"description\":\"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.\",\"sameAs\":[\"https:\\\/\\\/x.com\\\/HuiQiQu\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/author\\\/hqiqu\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Long-term prospective clinical follow-up after BRCA1\/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies (Contributed by Prof. D Gareth Evans) - JMG Contact blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jmg\/2014\/07\/23\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\/","og_locale":"en_US","og_type":"article","og_title":"Long-term prospective clinical follow-up after BRCA1\/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies (Contributed by Prof. D Gareth Evans) - JMG Contact blog","og_description":"The risks of breast cancer associated with gene faults in BRCA1 and BRCA2 have been reported to vary from as little as 30% (especially BRCA2) to as high as 90% by age 70 years. However, most studies that assessed risk look backwards at what has happened in families rather than forwards. These studies make adjustments [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jmg\/2014\/07\/23\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\/","og_site_name":"JMG Contact blog","article_published_time":"2014-07-23T03:57:51+00:00","article_modified_time":"2026-02-25T19:44:43+00:00","og_image":[{"width":640,"height":480,"url":"https:\/\/blogs.bmj.com\/jmg\/files\/2014\/07\/evanstonightPic.jpg","type":"image\/jpeg"}],"author":"hqqu","twitter_card":"summary_large_image","twitter_creator":"@HuiQiQu","twitter_misc":{"Written by":"hqqu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jmg\/2014\/07\/23\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2014\/07\/23\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\/"},"author":{"name":"hqqu","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b"},"headline":"Long-term prospective clinical follow-up after BRCA1\/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies (Contributed by Prof. D Gareth Evans)","datePublished":"2014-07-23T03:57:51+00:00","dateModified":"2026-02-25T19:44:43+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2014\/07\/23\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\/"},"wordCount":144,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2014\/07\/23\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2014\/07\/evanstonightPic-300x225.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jmg\/2014\/07\/23\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jmg\/2014\/07\/23\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\/","url":"https:\/\/blogs.bmj.com\/jmg\/2014\/07\/23\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\/","name":"Long-term prospective clinical follow-up after BRCA1\/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies (Contributed by Prof. D Gareth Evans) - JMG Contact blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2014\/07\/23\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\/#primaryimage"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2014\/07\/23\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2014\/07\/evanstonightPic-300x225.jpg","datePublished":"2014-07-23T03:57:51+00:00","dateModified":"2026-02-25T19:44:43+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2014\/07\/23\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jmg\/2014\/07\/23\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/2014\/07\/23\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\/#primaryimage","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2014\/07\/evanstonightPic.jpg","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2014\/07\/evanstonightPic.jpg","width":640,"height":480},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jmg\/2014\/07\/23\/long-term-prospective-clinical-follow-up-after-brca12-presymptomatic-testing-brca2-risks-higher-than-in-adjusted-retrospective-studies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jmg\/"},{"@type":"ListItem","position":2,"name":"Long-term prospective clinical follow-up after BRCA1\/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies (Contributed by Prof. D Gareth Evans)"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jmg\/#website","url":"https:\/\/blogs.bmj.com\/jmg\/","name":"JMG Contact blog","description":"JMG Contact blog","publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jmg\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jmg\/#organization","name":"JMG Contact blog","url":"https:\/\/blogs.bmj.com\/jmg\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","width":300,"height":34,"caption":"JMG Contact blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b","name":"hqqu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","caption":"hqqu"},"description":"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.","sameAs":["https:\/\/x.com\/HuiQiQu"],"url":"https:\/\/blogs.bmj.com\/jmg\/author\/hqiqu\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/users\/123"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/comments?post=661"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/661\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/media?parent=661"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/categories?post=661"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/tags?post=661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}